Moderna stock rose after positive melanoma vaccine trial results.

The article mentions Moderna shares rose over 15% after the company and Merck reported five‑year phase 2 data showing their individualized mRNA therapy, intismeran autogene, reduced the risk of recurrence or death by 49% when added to Keytruda in high‑risk melanoma patients.

Moderna and Merck announced five‑year follow‑up results from a phase 2 study of an experimental individualized mRNA therapy for high‑risk melanoma. The trial tested intismeran autogene combined with Merck’s Keytruda in patients who had surgery for stage III/IV melanoma. The article mentions Moderna’s shares rose more than 15% by the close of trading after the news. The companies say they are also testing the approach in other tumor types. Key facts: - The phase 2 five‑year follow‑up reported a 49% lower risk of recurrence or death for patients receiving intismeran autogene plus Keytruda versus Keytruda alone. - The study population was patients with high‑risk melanoma who had undergone surgery. - Intismeran autogene is described as an individualized therapy designed to trigger an antitumor immune response based on the unique mutations in a patient’s tumor. - Moderna and Merck have other clinical trials underway to evaluate the technology in lung, kidney, and bladder cancers. - Company executives described the results as a meaningful milestone and said they continue to invest in mRNA oncology research. Summary: The reported five‑year phase 2 findings were presented as longer‑term evidence that the individualized mRNA therapy added to Keytruda reduced recurrence or death in the studied group, and the article notes a notable move in Moderna’s share price after the announcement. The companies are pursuing additional trials in other tumor types. Undetermined at this time.